Why the study?
How SARS-CoV-2 circumvents Nsp1-mediated suppression of host protein synthesis to enable viral translation, and whether this mechanism can be targeted therapeutically, remained unclear.
Targeting the SL1 region of the SARS-CoV-2 5' UTR with antisense oligonucleotides inhibits viral translation and protects against SARS-CoV-2-induced lethality in a mouse model.
Answers are grounded in this paper and cite their sources.
Should not yet change COVID-19 care; leaves open human translation of SL1-targeted ASOs.
SARS-CoV-2 is a highly pathogenic virus that evades antiviral immunity by interfering with host protein synthesis, mRNA stability, and protein trafficking. The SARS-CoV-2 nonstructural protein 1 (Nsp1) uses its C-terminal domain to block the messenger RNA (mRNA) entry channel of the 40S ribosome to inhibit host protein synthesis. However, how SARS-CoV-2 circumvents Nsp1-mediated suppression for viral protein synthesis and if the mechanism can be targeted therapeutically remain unclear. Here, we show that N- and C-terminal domains of Nsp1 coordinate to drive a tuned ratio of viral to host translation, likely to maintain a certain level of host fitness while maximizing replication. We reveal that the stem-loop 1 (SL1) region of the SARS-CoV-2 5' untranslated region (5' UTR) is necessary and sufficient to evade Nsp1-mediated translational suppression. Targeting SL1 with locked nucleic acid antisense oligonucleotides inhibits viral translation and makes SARS-CoV-2 5' UTR vulnerable to Nsp1 suppression, hindering viral replication in vitro at a nanomolar concentration, as well as providing protection against SARS-CoV-2-induced lethality in transgenic mice expressing human ACE2. Thus, SL1 allows Nsp1 to switch infected cells from host to SARS-CoV-2 translation, presenting a therapeutic target against COVID-19 that is conserved among immune-evasive variants. This unique strategy of unleashing a virus' own virulence mechanism against itself could force a critical trade-off between drug resistance and pathogenicity.
No takes yet. Share an insight, caveat, or question.
Vora et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: